VolitionRx Limited has completed the validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan. This achievement enables full automation in central laboratories through the IDS i10 automated analyzer platform, marking a significant advancement in veterinary diagnostics.
The transition from manual plates to automated processing is expected to support faster turnaround and higher throughput as demand grows. More than 1,700 veterinary hospitals in Japan are already registered to use the test, indicating substantial market adoption. Japan's approximately seven million pet dogs represent a significant addressable market for this technology.
The automated platform aligns with the same system used for Volition's human Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover products, underscoring cross-platform synergy. This strategic alignment allows for shared technological infrastructure and potentially accelerates development across both human and veterinary diagnostic applications.
Volition is a multi-national company focused on advancing the science of epigenetics and is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company's website at https://volition.com/.
The automation validation represents a critical step in scaling veterinary cancer diagnostics, potentially enabling widespread screening that could detect cancers earlier in pets. This development could have significant implications for the veterinary diagnostics industry, potentially setting new standards for efficiency and accessibility in animal healthcare. The technology's alignment with human diagnostic platforms suggests potential for knowledge transfer and accelerated innovation across both sectors.
For investors and industry observers, this milestone demonstrates Volition's execution capability in bringing epigenetic diagnostics to market and its strategic focus on both human and veterinary applications. The company's progress in Japan, a market with high pet ownership rates and advanced veterinary care standards, could serve as a model for expansion into other regions. The full press release can be viewed at https://ibn.fm/k076y.
